The FDA has granted Bristol-Myers Squibb and Sanofi-Aventis a six month extension in term of Pediatric extension to its OB listed patent no. 4847265 for Plavix (clopidogrel). The normal expiry was Nov 17, 2011 which after extension of six months now going to expire on May 17,2012. This extension was awarded for the study of Plavix in infants.
Plavix is one of the highly selling drug in US after Lipitor for the cardiovascualr disease. So now they can keep away the generic players from the markets for more six months.
Plavix is one of the highly selling drug in US after Lipitor for the cardiovascualr disease. So now they can keep away the generic players from the markets for more six months.
No comments:
Post a Comment